Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RJB-0402
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RJB-0402 is a liver-targeting adeno-associated virus vector-based gene therapy that drives over expression of FGF21, which is investigated for the treatment of arrhythmogenic cardiomyopathy.
Brand Name : RJB-0402
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 09, 2023
Lead Product(s) : RJB-0402
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Rejuvenate Biomed Announces Positive Results from Phase 1b Clinical Trial with RJx-01 in Sarcopenia
Details : RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Brand Name : RJx-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : Galantamine Hydrobromide,Metformin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RJx-01
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Details : RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech d...
Brand Name : RJx-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2022
Lead Product(s) : RJx-01
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?